在惰性癌症的关键试验中监测整体存活率
Thomas R Fleming1, Lisa V Hampson2, Bharani Bharani-Dharan3
1Department of Biostatistics, University of Washington, Seattle, WA, US.
Statistics in biopharmaceutical research
|May 26, 2025
概括
在惰性癌症中监测整体存活率 (OS) 具有挑战性,因为存活时间很长. 本文提出了新的OS监测指南,用于临床试验,以早期检测有害影响.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 生物统计学 生物统计学
背景情况:
- 惰性癌症的整体存活率 (OS) 很长,这使得在试验中难以进行最终的OS评估.
- 经常使用无进展生存等中间结果,但可以在以后的数据中掩盖有关OS趋势.
- 这增加了对量化方法的兴趣,以监测OS和潜在危害.
研究的目的:
- 提出新的OS监测指南,专门针对惰性癌症.
- 为监管决策提供一个框架,以考虑潜在的破坏性OS影响.
主要方法:
- 制定了针对惰性癌症量身定制的实用性OS监测指南.
- 在2型糖尿病患者心血管安全试验中使用的FDA指导方针上建模了方法.
- 用案例研究说明了拟议的指导方针.
主要成果:
- 拟议的指导方针旨在提供早期检测潜在有害的OS趋势.
- 该方法提供了一种定量方法,以支持在惰性癌症试验中的监管监督.
- 案例研究应用证明了指南的实际实用性.
结论:
- 有效的OS监测对于因长时间的存活率而导致的惰性癌症至关重要.
- 拟议的指导方针提供了一个结构化的方法,以平衡试验可行性与患者安全.
- 这些指导方针可以帮助做出明智的监管决策,以对惰性癌症进行干预.
相关概念视频
Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Clinical Trials: Overview
4.6K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.6K
Kaplan-Meier Approach
581
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
581
Clinical Trials
10.2K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
10.2K
Comparing the Survival Analysis of Two or More Groups
565
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
565


